spacer
home > pmps > winter 2001 > medical and pharmaceutical translation - the need for a specialist
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Medical and Pharmaceutical Translation - The Need for a Specialist

The globalisation of business has led to the need for the medical and pharmaceutical industries to simultaneously satisfy the requirements of regulatory authorities, including submission of information in a variety of languages. For example, those pharmaceutical companies submitting a marketing authorisation application in order to fulfil EU dossier requirements must provide a summary of product characteristics (Part IB), labelling information and a patient information leaflet in every official EU language. In addition, there are often layout requirements and the need to use phrase constructions that are fixed and mandatory. Finally, similar requirements also apply to CE Marking related documentation for the medical devices market. Only a professional and specialised company can provide the expertise needed for this sort of demanding translation work.

To work as a translator, a person must not only be fluent in multiple languages, but also have the academic foundation upon which to base a thorough understanding of the current status and terminology of highly specialised areas of business, law, technology, economy and health care. The translator must have a solid linguistic education.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Arthur P. Leccese of Wilkens c.s. in the Netherlands Dr Arthur P. Leccese holds a PhD in Physiological Psychology. For two decades, he conducted research and taught courses in psychopharmacology in the US After working with several pharmaceutical firms in the Netherlands, he joined Wilkens c.s. as a Translator of medical-pharmaceutical texts.
spacer
Arthur P. Leccese
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement